“finances” Archives

Entry Author Date Location
In Murky Regulatory Filings, Idaciti Seeks to Bring Transparency 02/17/16 Boulder/Denver
Acucela Pins Down $162M IPO in Japan to Develop Eye Drugs 02/04/14 Seattle
Which Regions Are Churning Out the Most Biotech IPOs? 11/04/13 National
Veracyte, Thyroid Cancer Diagnostic Player, Pulls Off IPO 10/30/13 San Francisco
21 Red Flags to Watch for in a Biotech Company 10/21/13 National
5 Things Biotechs Should Do to Take Advantage of The Boom 09/05/13 New York
Former Dendreon CEO and Dendreon Bull Start New Biotech Hedge Fund 09/03/13 Seattle
The Biotech IPO Scorecard: Who’s Up, Who’s Down in 2013 06/03/13 National
Kineta, Scouring the World for Cash, Finds Oil Money 05/21/13 Seattle
Tableau on the Run: IPO Underscores Seattle Big Data Leadership 05/20/13 Seattle
Blaze Bioscience Caps Off $8.5M Financing, Charges Toward Clinic 02/22/13 Seattle
Seattle Genetics Gets $138M in First-Year Sales of Cancer Drug 02/12/13 Seattle
Foresite Capital Closes $100M Fund for Late-Stage Biotechs 01/31/13 San Francisco
Crowdfunding Is Coming to Biotech, so Get Ready for a Wild Ride 01/28/13 National
Who Are Biotech’s New Go-To Investment Bankers? 11/12/12 National
The New Power Players in Drug R&D Are Wearing Bright T-Shirts 10/29/12 National
The Best Boring Companies in Biotech 07/09/12 National
Omeros Pockets $28M in Stock Sale 06/28/12 Seattle
Oncothyreon Grabs $47M in Stock Offering 03/29/12 Seattle
Biotech Lagging Behind Go-Go Web Valuations, Survey Says 03/20/12 National
OncoGenex Snags $50M for Prostate Cancer Drug Plan 03/16/12 Seattle
Five Myths You’ll Hear This Week at the JP Morgan Healthcare Conference 01/09/12 National
PacBio Slashes 28 Percent of Its Workforce to Conserve Cash 09/20/11 San Francisco
Vivus Adds $45.8M 08/23/11 San Francisco
Exclusive: Pathway Medical Technologies To Be Acquired by Bayer’s Medrad Unit for $125M 08/19/11 Seattle
Time to Cure Cancer or Stash Cash Under the Mattress? 08/15/11 National
OncoGenex Drops on Trial Delay 08/05/11 Seattle
PacBio Hits Goal in Debut Quarter With New DNA Sequencer, Stock Tanks Anyway 08/04/11 San Francisco
Complete Genomics Stock Falls on Sales Decline, as Sequencing Gets Cheaper 08/04/11 San Francisco
Illumina Sales Climb 36%, Profits Flat 07/26/11 San Diego
Page 1 of 11 next page »